Moderna's personalized cancer vaccine (mRNA-4157, combined with Keytruda) showed a 44% reduction in recurrence-free survival in melanoma. Phase 3 is underway. An November 15 PDUFA could make it the first approved mRNA cancer vaccine.
July 20, 2026 · mRNA · $MRNAAlnylam's nucapsiran — an RNAi therapeutic targeting angiotensinogen — showed sustained blood pressure reduction with quarterly dosing. Phase 2 data in Q4 2026 could position it as the first RNAi drug for hypertension.
July 17, 2026 · Rare Disease · $ALNYGilead's lenacapavir showed 100% efficacy in HIV PrEP (prevention) in the PURPOSE 2 trial. Twice-yearly dosing could transform HIV prevention. Phase 3 data expected in Q4 2026.
July 16, 2026 · Infectious Disease · $GILD